Erratum to: Evaluation of resistance mechanisms and serotype and genotype distributions of macrolide-resistant strains in clinical isolates of Streptococcus pneumoniae in Aydın, Turkey

Telli, Murat; Eyigör, Mete; Gültekin, Berna; Aydın, Neriman

doi:10.1007/s10156-011-0290-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Turkey, macrolide resistance among S. pneumoniae has increased from 7% to 29% (11)(12)(13)(14)(15). Although Telli et al (16) reported higher percentages (40%) in 2007-2009, the macrolide resistance rate in this study was 22.5%, which is similar to the result of EARRSS, but higher than the rates reported previously in our hospital (13,14). S2 S3 S11 S13 S18 S6 S15 S16 S17 S4 0.1 0.2 (17).…”

Section: Discussionsupporting

confidence: 51%

Phenotypes and Genotypes of Macrolide-Resistant Streptococcus Pneumoniae

Sirekbasan¹,

Gönüllü²,

Sirekbasan³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

Streptococcus pneumoniae (S. pneumoniae) is a major pathogen of bacterial pneumonia, meningitis, sinusitis and otitis media. Antimicrobial resistance in S. pneumoniae, including macrolide resistance, has been a growing problem in recent years due to the increasing numbers of cases with treatment failures of infections caused by macrolide-resistant pneumococci (1).Macrolide resistance in S. pneumoniae is mediated by: the erm (B) gene encodes methylation of the ribosomal macrolide target sites and mef (A) encodes the drug efflux. Deterioration of riboproteins L4 and L22 and mutations in the 23S rRNA genes are involved in the other less common mechanisms (2).In this study, we analyzed the distribution of the phenotypes, genotypes, and clonal relatedness of macrolide-resistant S. pneumoniae strains isolated in our hospital. MATERIALS AND METHODSEighty S. pneumoniae strains were collected between January 2008 and September 2009 in the Department of Microbiology of the Cerrahpaşa Faculty of Medicine. Ethics committee approval was received for this study from the Ethics Committee of Cerrahpaşa Faculty of Medicine. Strains were isolated mostly from sputum. The remaining isolates were from tracheal aspirates, bronchoalveolar lavage fluid, nasal swab and blood culture.S. pneumoniae isolates were identified based on conventional microbiological methods. Antibiotic susceptibility testing was performed with the disc diffusion method (3).Macrolide resistance phenotypes were determined by Montanari et al. (4) : 11.11.2013 Accepted: 23.11.2014 • DOI: 10.5152/balkanmedj.2015 Available at www.balkanmedicaljournal.org Cite this article as: Sirekbasan L, Gönüllü N, Sirekbasan S, Kuşkucu M, Midilli K. Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae. Balkan Med J 2015;32:84-8. Copyright 2015 © Trakya University Faculty of MedicineBalkan Med J 2015;32:84-8 Original Article | 84MICs of macrolides (erythromycin, clarithromycin and azithromycin), lincosamides (clindamycin), streptogramins (quinupristin-dalfopristin) and penicillin G were measured by E-test (AB Biodisk; Solna, Sweden). The strain S. pneumoniae ATCC 49619 was used as a control strain. Detection of erythromycin-resistance genesA PCR method was used for the detection of erythromycinresistance genes (5). Bacterial DNA was isolated using a DNA isolation kit (Roche Diagnostic; Mannheim, Germany). All PCR mixtures contain a volume of 25 µL with 5µL of target DNA, 0.5 µL of each primer (25 mM), 1.5 µL of 25 mM MgCl 2 , 0.5 µL of dNTP mixture (25 mM each), 0.125 µL of Taq DNA polymerase (5 U/µL) and 2.5 µL of 10X buffer (MBI; Fermentas, Lithuania). PCR for both genes was performed on PTC-200 (Peltier Thermal Cycler; MJ Research, USA). Cycling conditions for amplification were: 5 min at 94°C, followed by 40 cycles of 1 min at 94°C, 1 min at 48°C and 1.5 min at 72°C, with a final 10 min incubation at 72°C. PCR products were separated on ethidium bromide stained 1.5% agarose gels. The expected sizes of amplification products for erm (B) and mef (A) were ...

show abstract

Section: Discussionsupporting

confidence: 51%

Phenotypes and Genotypes of Macrolide-Resistant Streptococcus Pneumoniae

Sirekbasan¹,

Gönüllü²,

Sirekbasan³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

show abstract

“…33 Several case series on the use of linezolid in Gram-positive bacterial meningitis other than pneumococci have also been reported, [34][35][36][37] as well as the superiority of linezolid to vancomycin in methicillin-resistant Staphylococcus aureus meningitis. 38 Moreover, resistance to linezolid in pneumococci has not been observed in Turkey 25,39,40 and is not a real problem in most parts of the world. 41 Thus, linezolid could be a potential option either alone or in combination, although this point of view must be supported by well-designed randomized clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Mortality indicators in pneumococcal meningitis: therapeutic implications

Erdem¹,

Elaldı²,

Öztoprak³

et al. 2014

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Ceftriaxone alone is not adequate in the management of pneumococcal meningitis due to penicillin-resistant pneumococci, which is a major concern worldwide. Although vancomycin showed a trend towards improving the prognosis of pneumococcal meningitis, significant correlation in statistical terms could not be established in this study. Thus, further studies are needed for the optimization of pneumococcal meningitis treatment.

show abstract

Erratum to: Evaluation of resistance mechanisms and serotype and genotype distributions of macrolide-resistant strains in clinical isolates of Streptococcus pneumoniae in Aydın, Turkey

Cited by 2 publications

References 0 publications

Phenotypes and Genotypes of Macrolide-Resistant Streptococcus Pneumoniae

Phenotypes and Genotypes of Macrolide-Resistant Streptococcus Pneumoniae

Mortality indicators in pneumococcal meningitis: therapeutic implications

Contact Info

Product

Resources

About